Copyright: Jacobio Pharmaceuticals Co., Ltd.   Beijing ICP preparation 17065868-1   



Address: Building F2, No. 88, Kechuang 6th Street, Beijing Economic Development Zone

Tel: +86  010-56315466

Fax: +86  010-56315314




Page view:

  January 12, 2018 - JAB-3068, a novel anti-tumor small molecular developed by Jacobio, had approved by FDA to advance to Phase I clinical trial. The IND application to cFDA was also under evaluation. The Phase I clinical trial will be held in US and China, the US trial is now in recruiting.